This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0191-18

### Tarceva (erlotinib)

<table>
<thead>
<tr>
<th>Override(s)</th>
<th>Approval Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior Authorization</td>
<td>1 year</td>
</tr>
<tr>
<td>Quantity Limit</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medications</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tarceva (erlotinib)</td>
<td>May be subject to quantity limit</td>
</tr>
</tbody>
</table>

### APPROVAL CRITERIA

Requests for Tarceva (erlotinib) may be approved if the following criteria are met:

I. Individual has a diagnosis of Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, with test results confirmed, **AND** when used as:
   A. First-line therapy; **OR**
   B. Subsequent or maintenance treatment of locally advanced or metastatic disease after at least one prior chemotherapy regimen;

**OR**

II. Individual has a diagnosis of either locally advanced, unresectable, or metastatic Pancreatic cancer; **AND**

III. Individual is using in combination with gemcitabine;

**OR**

IV. Individual has a diagnosis of Bone cancer; **AND**

V. Individual is using as monotherapy for recurrent chordoma (NCCN 2A);

**OR**

VI. Individual has a diagnosis of relapsed or surgically unresectable stage IV Kidney cancer (NCCN 2A);

**OR**

VII. Individual has a diagnosis of Central Nervous System Cancers for recurrent brain metastases if active against the primary tumor (NSCLC) (NCCN 2A).
## Market Applicability

| Market | DC | FL & FHK | FL MMA | FL LTC | GA | KS | KY | MD | NJ | NV | NY | TN | TX | WA |
|--------|----|---------|-------|-------|----|----|----|----|----|----|----|----|----|----|----|
| Applicable | X | X | NA | NA | X | NA | X | X | X | X | X | NA | NA | X |

*FHK - Florida Healthy Kids

---

## State Specific Mandates

<table>
<thead>
<tr>
<th>State name</th>
<th>Date effective</th>
<th>Mandate details (including specific bill if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

---

### Key References:


DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.


---

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0191-18